Literature DB >> 11239922

Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat.

A Kask1, E Vasar, L T Heidmets, L Allikmets, J E Wikberg.   

Abstract

The effects of neuropeptide Y Y(5) receptor antagonist (trans-naphtalene-1-sulphonic acid [4-[(4-amino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl]-amide hydrochloride; CGP71683A), on food intake, anxiety and locomotor activity were studied. CGP71683A (1-10 mg/kg, i.p.) dose-dependently decreased nocturnal and fasting-induced food intake. CGP71683A did not have an anxiogenic-like effect in the rat social interaction test. In the elevated plus-maze test, where novel neuropeptide Y Y(1) receptor antagonist (2R)-5-([amino(imino)methyl)amino)-2-[(2.2-diphenylacetyl)-amino]-N-[(1R)-1-(4-hydroxyphenyl)ethyl-pentanamide (H 409/22) had anxiogenic-like effect, CGP71683A was inactive. In the open-field test, carried out immediately after the elevated plus-maze test, CGP71683A inhibited horizontal and vertical activity. CGP71683A did modify the habituation of locomotor response in novel environment. These data show that the inhibition of food intake induced by CGP71683A could not be explained by increased fearfulness, a state that is induced by neuropeptide Y Y(1) receptor antagonists. Thus, our data, obtained with first neuropeptide Y Y(5) receptor antagonist CGP71683A, suggest that in contrast to the neuropeptide Y Y(1) receptor, Y(5) receptor is not involved in tonic neuropeptide Y-induced anxiolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239922     DOI: 10.1016/s0014-2999(01)00768-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs.

Authors:  Anne Lecklin; Ingrid Lundell; Suvi Salmela; Pekka T Männistö; Annette G Beck-Sickinger; Dan Larhammar
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 2.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 3.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

4.  A role for neuropeptide Y Y5 but not the Y1-receptor subtype in food deprivation-induced reinstatement of heroin seeking in the rat.

Authors:  Tia Maric; Firas Sedki; Danielle Chafetz; Nick Schoela; Uri Shalev
Journal:  Psychopharmacology (Berl)       Date:  2011-06-01       Impact factor: 4.530

5.  Distribution of NPY Y5-like immunoreactivity in the rat brain.

Authors:  S Michelle Morin; Donald R Gehlert
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

6.  Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig.

Authors:  Anne Lecklin; Ingrid Lundell; Leena Paananen; Jarl E S Wikberg; Pekka T Männistö; Dan Larhammar
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

7.  Effect of depression and suicidal behavior on neuropeptide Y (NPY) and its receptors in the adult human brain: A postmortem study.

Authors:  Anuradha Sharma; Xinguo Ren; Hui Zhang; Ghanshyam N Pandey
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-08-17       Impact factor: 5.067

8.  The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice.

Authors:  Rose-Marie Karlsson; Jessica S Choe; Heather A Cameron; Annika Thorsell; Jacqueline N Crawley; Andrew Holmes; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2007-09-22       Impact factor: 4.530

Review 9.  Neuropeptide Y in Alcohol Addiction and Affective Disorders.

Authors:  Annika Thorsell; Aleksander A Mathé
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

Review 10.  Neuropeptide Y: A stressful review.

Authors:  Florian Reichmann; Peter Holzer
Journal:  Neuropeptides       Date:  2015-09-30       Impact factor: 3.286

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.